82 Year Old with Pigmented Lesion

  • Robert A. Norman
  • Justin Endo
Chapter
Part of the Clinical Cases in Dermatology book series (CLIDADE)

Abstract

The patient showed a dark and irregular lesion in an area of chronically sun exposed skin (Fig. 18.1). He had no previous treatment. A biopsy was performed.

Keywords

Hyde Imiquimod 

References

  1. Bolognia J, Jorizzo JL, Rapini RP. Dermatology. St. Louis: Mosby/Elsevier; 2008.Google Scholar
  2. Bub JL, Berg D, Slee A, Odland PB. Management of lentigo maligna and lentigo maligna melanoma with staged excision: a 5-year follow-up. Arch Dermatol. 2004;140(5):552–8.PubMedCrossRefGoogle Scholar
  3. Hazan C, Dusza SW, Delgado R, Busam KJ, Halpern AC, Nehal KS. Staged excision for lentigo maligna and lentigo maligna melanoma: a retrospective analysis of 117 cases. J Am Acad Dermatol. 2008;58(1):142–8.PubMedCrossRefGoogle Scholar
  4. Hyde MA, Hadley ML, Tristani-Firouzi P, Goldgar D, Bowen GM. A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions. Arch Dermatol. 2012;148(5):592–6.Google Scholar
  5. James William D, Berger Timothy G, et al. Andrews’ diseases of the skin: clinical dermatology. New York: Saunders Elsevier; 2006.Google Scholar
  6. McKenna JK, Florell SR, Goldman GD, Bowen GM. Lentigo maligna/lentigo maligna melanoma: current state of diagnosis and treatment. Dermatol Surg. 2006;32(4):493–504.PubMedCrossRefGoogle Scholar
  7. Stevenson O, Ahmed I. Lentigo maligna: prognosis and treatment options. Am J Clin Dermatol. 2005;6(3):151–64.PubMedCrossRefGoogle Scholar
  8. Weinstock MA, Sober AJ. The risk of progression of lentigo maligna to lentigo maligna melanoma. Br J Dermatol. 1987;116(3):303–10.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • Robert A. Norman
    • 1
  • Justin Endo
    • 2
  1. 1.TampaUSA
  2. 2.MadisonUSA

Personalised recommendations